Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Very Strong
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Website
N/ATelephone
61.2.9874.8761
Address
Suite 301 55 Lime Street Sydney, New South Wales (NSW) 2000
Description
CardieX Ltd. engages in designing, manufacturing, and marketing medical devices used in cardiovascular health management. It operates through the following geographical segments: Americas, Europe, and Asia Pacific. The Americas segment includes pharmaceutical trials business. The Europe segment focuses on the Middle East and Africa. The Asia Pacific segment is involved in the operations of Asia, Australia, and New Zealand. The company was founded by Ross Harricks, Niall Charles Edgar Cairns, Craig R. Cooper, and Michael Francis O'Rourke in 1994 and is headquartered in Sydney, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.05 - 0.17
Trade Value (12mth)
AU$3,883.00
1 week
-1.61%
1 month
-12.86%
YTD
-24.69%
1 year
-65.04%
All time high
7.82
EPS 3 yr Growth
187.800%
EBITDA Margin
N/A
Operating Cashflow
-$10m
Free Cash Flow Return
N/A
ROIC
N/A
Interest Coverage
N/A
Quick Ratio
N/A
Shares on Issue (Fully Dilluted)
189m
HALO Sector
Healthcare
Next Company Report Date
29-Aug-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
26 June 24 |
Application for quotation of securities - CDX
×
Application for quotation of securities - CDX |
18 June 24 |
Cardiex Sales and Operations Update
×
Cardiex Sales and Operations Update |
17 June 24 |
Options Prospectus
×
Options Prospectus |
17 June 24 |
Proposed issue of securities - CDX
×
Proposed issue of securities - CDX |
03 June 24 |
Results of June 2024 Extraordinary General Meeting
×
Results of June 2024 Extraordinary General Meeting |
29 May 24 |
Ceasing to be a substantial holder
×
Ceasing to be a substantial holder |
30 April 24 |
Change in substantial holding
×
Change in substantial holding |
26 April 24 |
Notice of Extraordinary General Meeting/Proxy Form
×
Notice of Extraordinary General Meeting/Proxy Form |
24 April 24 |
March Quarterly Appendix 4C
×
March Quarterly Appendix 4C |
24 April 24 |
March Quarterly Activities Report
×
March Quarterly Activities Report |
24 April 24 |
Corporate Webinar Presentation
×
Corporate Webinar Presentation |
22 April 24 |
Change in substantial holding
×
Change in substantial holding |
08 April 24 |
Cardiex Corporate Update Webinar
×
Cardiex Corporate Update Webinar |
08 April 24 |
Appendix 3Y x2
×
Appendix 3Y x2 |
02 April 24 |
Completion of Wearable Study and New Wearable Patent
×
Completion of Wearable Study and New Wearable Patent |
27 March 24 |
Becoming a substantial holder
×
Becoming a substantial holder |
14 March 24 |
Funding Commitment Agreement Update
×
Funding Commitment Agreement Update |
01 March 24 |
Appendix 3X
×
Appendix 3X |
29 February 24 |
Half Yearly Report and Accounts
×
Half Yearly Report and Accounts |
27 February 24 |
Application for quotation of securities - CDX
×
Application for quotation of securities - CDX |
26 February 24 |
ASX Relisting and Market Update
×
ASX Relisting and Market Update |
26 February 24 |
Notification of cessation of securities - CDX
×
Notification of cessation of securities - CDX |
26 February 24 |
Appendix 3Y x 3
×
Appendix 3Y x 3 |
09 October 23 |
CardieX - Go-to-Market (GTM) & Product Development Update
×
CardieX - Go-to-Market (GTM) & Product Development Update |
04 October 23 |
Corporate & Operating Update
×
Corporate & Operating Update |
03 October 23 |
Appendix 3Z
×
Appendix 3Z |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.